Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study
The Journal of Clinical Pharmacology · 2026-06 · 66 (6)
DOI: 10.1002/jcph.70219 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.05.2026. Verfasst von Christina Gade und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Caffeine, Liver, Theophylline. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medicinpuljen.
Abstract (Originalsprache)
Obesity‐related metabolic and hepatic alterations may influence drug metabolism via cytochrome P450 enzymes. While adult studies suggest altered CYP1A2 activity in obesity, data in pediatric populations remain limited and inconclusive. The objective was to assess the in vivo CYP1A2 phenotype in adolescents aged 11‐18 years with and without obesity, and to explore sex‐based differences in enzyme activity within this age group. In this open‐label pharmacokinetic study, which is a part of the CYTONOX study, 65 adolescents aged 11–18 years were included, comprising 30 individuals with obesity and 35 without obesity, recruited based on feasibility. The CYP1A2 phenotype was assessed using urinary paraxanthine/caffeine metabolic ratios following caffeine exposure. Hepatic fat content was measured via magnetic resonance spectroscopy. The study received approval from the Danish Health Authorities (EudraCT: 2014‐004554‐34) and the Regional Ethical Committee of Zealand (SJ‐455). Despite metabolic differences and increased hepatic fat in the obese group, the CYP1A2 phenotype did not differ significantly between obese and non‐obese adolescents (mean log10 urinary metabolic ratio: 0.82 vs 0.80; P = .93). No sex‐based differences were observed. Obesity in adolescents does not appear to significantly impact CYP1A2 phenotype assessed by urinary metabolic ratio, in contrast to selected studies in adults. These findings suggest preserved CYP1A2 function during adolescence despite metabolic and hepatic changes. Further longitudinal studies are needed to elucidate the age‐related progression of hepatic enzyme activity in context of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
- Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Huddinge, Sweden.
- Children's Obesity Clinic, European Association for the Study of Obesity (EASO), Department of Pediatrics, Zealand University Hospital, Holbaek, Denmark.
- Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Christina Gade, Kim Dalhoff
Förderung
- Medicinpuljen
Zitieren
APA
Gade, C., Ullah, S., Dalhoff, K., Andersen, J. T., Riis, T., Holm, J. C., & Lausten-Thomsen, U. (2026). Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study. The Journal of Clinical Pharmacology, 66(6). https://doi.org/10.1002/jcph.70219
Vancouver
Gade C, Ullah S, Dalhoff K, Andersen JT, Riis T, Holm JC, et al. Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study. The Journal of Clinical Pharmacology. 2026;66(6). doi:10.1002/jcph.70219
BibTeX
@article{Gade2026,
author = {Gade, Christina and Ullah, Shahid and Dalhoff, Kim and Andersen, Jon Trærup and Riis, Troels and Holm, Jens Christian and Lausten-Thomsen, Ulrik},
title = {Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {6},
doi = {10.1002/jcph.70219}
}
EUVIMED